Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
Posted: October 15, 2024 at 2:50 am
Data presentations highlight the results for FILSPARI® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line treatment, and in combination with other therapies
Go here to read the rest:
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
Posted in Global News Feed
Comments Off on Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue…
Posted: October 15, 2024 at 2:50 am
WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to update shareholders on multi-billion dollar asset valuation following this week’s $1b+ revenue potential announcement.
Read more from the original source:
Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue...
Posted in Global News Feed
Comments Off on Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue…
Metagenomi Presents Compact SMART Editing Platform at AIChE 7th International Conference on CRISPR Technologies
Posted: October 15, 2024 at 2:50 am
Poster presentation highlights SMART adenine base editors (ABEs)small enough to be packaged into a single adeno-associated virus (AAV)
Go here to see the original:
Metagenomi Presents Compact SMART Editing Platform at AIChE 7th International Conference on CRISPR Technologies
Posted in Global News Feed
Comments Off on Metagenomi Presents Compact SMART Editing Platform at AIChE 7th International Conference on CRISPR Technologies
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular &…
Posted: October 15, 2024 at 2:50 am
Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response
Read the rest here:
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular &...
Posted in Global News Feed
Comments Off on argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular &…
Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024
Posted: October 15, 2024 at 2:50 am
ORION CORPORATION PRESS RELEASE 15 OCTOBER 2024 at 9.00 EEST
Follow this link:
Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024
Posted in Global News Feed
Comments Off on Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024
Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer
Posted: October 15, 2024 at 2:50 am
Avacta Group plc
Read the original post:
Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer
Posted in Global News Feed
Comments Off on Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer
Former UK Prime Minister David Cameron Joins Oxford-Harrington Rare Disease Centre (OHC) as Chair of its Advisory Council
Posted: October 15, 2024 at 2:50 am
Lord Cameron will lead international efforts to drive the OHC’s mission of delivering 40 new therapies for rare diseases into clinical trials over the next ten years
Read the original post:
Former UK Prime Minister David Cameron Joins Oxford-Harrington Rare Disease Centre (OHC) as Chair of its Advisory Council
Posted in Global News Feed
Comments Off on Former UK Prime Minister David Cameron Joins Oxford-Harrington Rare Disease Centre (OHC) as Chair of its Advisory Council
Umoja Biopharma Announces Poster Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
Posted: October 7, 2024 at 2:37 am
SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies in oncology and autoimmunity, today announced that Umoja will present two poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held November 6-10, 2024, in Houston, Texas and virtually.
See the original post here:
Umoja Biopharma Announces Poster Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
Posted in Global News Feed
Comments Off on Umoja Biopharma Announces Poster Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Posted: October 7, 2024 at 2:37 am
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, Texas, from November 6-10, 2024. The company plans to present preclinical data from its tumor-activated SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR) format.
Read the original:
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Posted in Global News Feed
Comments Off on Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
Posted: October 7, 2024 at 2:37 am
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.
Read the original:
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
Posted in Global News Feed
Comments Off on BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
